Welcome to our dedicated page for Opgen SEC filings (Ticker: OPGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking antibiotic-resistant pathogen R&D spending can be daunting when OpGen releases pages of FDA correspondence, genomic data tables, and complex risk factors. Investors hunting for “OpGen insider trading Form 4 transactions” or clinicians asking “Where is the OpGen quarterly earnings report 10-Q filing?” often wade through EDGAR manually. Stock Titan eliminates that grind with AI-powered summaries that turn technical language into clear, actionable insight—OpGen SEC filings explained simply.
Our platform captures every submission—10-K, 10-Q, 8-K, S-1, and, crucially, “OpGen Form 4 insider transactions real-time”—within seconds of hitting the SEC. The AI engine highlights what matters: R&D expense swings in the “OpGen annual report 10-K simplified,” revenue from Acuitas Lighthouse services in the “OpGen earnings report filing analysis,” and grant milestones disclosed in “OpGen 8-K material events explained.” Interactive charts map “OpGen executive stock transactions Form 4” against share price so you can spot patterns before the next financing round.
Need deeper context? Expert commentary connects each disclosure to OpGen’s precision-medicine mission—showing how fresh capital funds new genomic assays or why an “OpGen proxy statement executive compensation” proposal affects runway when cash burn is tight. With real-time filing updates, comprehensive coverage, and tools for understanding OpGen SEC documents with AI, Stock Titan turns regulatory complexity into confident decisions—no microscope required.
OpGen, Inc. has pivoted from infectious disease diagnostics to financial services and fintech through its CapForce subsidiary, which provides listing sponsorship and consulting services. For the nine months ended September 30, 2025, OpGen generated $4,000,000 of revenue from a single international listing sponsorship client, but reported no revenue in Q3 2025.
The company posted Q3 2025 net loss of $608,730, yet remained profitable year-to-date with $2,493,129 of net income, driven by the new business line and tight operating expenses. At September 30, 2025, OpGen held $414,211 in cash and cash equivalents, $302,262 of restricted cash, a $5,000,000 equity investment in the client, and $4,043,838 of accounts receivable tied to that same relationship, while stockholders’ equity increased to $10,157,965 from $7,380,628 at year-end 2024.
Liquidity relies heavily on a financing arrangement with controlling stockholder AEI Capital Ltd., under which OpGen may sell up to an additional $7,000,000 of common stock through December 31, 2025; management believes this, together with current cash, can fund operations for more than 12 months. The company’s common stock was delisted from Nasdaq following failure to meet the stockholders’ equity listing standard and now trades on the OTC Markets Pink Limited Market under the symbol OPGN, and the business is highly concentrated, with one customer representing 99% of accounts receivable and 100% of 2025 year-to-date revenue.
FAQ
What is the current stock price of Opgen (OPGN)?
What is the market cap of Opgen (OPGN)?
